Cutaneous Squamous Cell Carcinoma

Adjuvant cemiplimab prolonged DFS compared with placebo for certain patients with cutaneous squamous cell carcinoma, according to the agent’s manufacturer.

The FDA approved cosibelimab-ipdl for the treatment of certain patients with cutaneous squamous cell carcinoma.

ORLANDO — Certain Mohs surgery repair types raised the risk for healing complications following adjuvant radiation therapy, according to a presentation at the American Society for Dermatologic Surgery Annual Meeting.

ORLANDO — Patients with localized high-risk cutaneous squamous cell carcinoma who received adjuvant radiation after clear margin surgery experienced decreased risk for local recurrence and nodal metastasis, according to study results.

Cemiplimab provided clinically meaningful responses for patients with metastatic and locally advanced cutaneous squamous cell carcinoma, according to a study.

The DecisionDx-SCC test successfully identified which patients with cutaneous squamous cell carcinoma would most likely benefit from adjuvant radiation therapy, according to a study.

Two randomized phase 3 trials of pembrolizumab — one in lung cancer and one in skin cancer — have been discontinued due to lack of efficacy, according to the agent’s manufacturer.

Prior radiotherapy was associated with progression-free survival in patients with metastatic cutaneous squamous cell carcinoma treated with cemiplimab, according to a study.

Patients with certain autoimmune and inflammatory conditions may develop cutaneous squamous cell carcinoma at higher rates than immunocompetent patients, according to a study.

Cutaneous squamous cell carcinoma risk rises with every subsequent occurrence while the time interval decreases, according to a large cohort study.